Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
- Conditions
- Platinum-resistant Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
- Interventions
- Biological: PembrolizumabBiological: NemvaleukinBiological: Nemvaleukin and Pembrolizumab Combination
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 456
- Registration Number
- NCT05092360
- Locations
- πΊπΈ
Rush University Medical Center, Chicago, Illinois, United States
πͺπΈHospital Clinico Universitario de Valencia, Valencia, Spain
π¨π³Taichung Veterans General Hospital, Taichung, Taiwan
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6
- Conditions
- Cutaneous MelanomaMucosal Melanoma
- Interventions
- Drug: Nemvaleukin Alfa SubcutaneousDrug: Nemvaleukin Alfa IntravenousDrug: Nemvaleukin Alfa Intravenous Less Frequent Dosing
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 180
- Registration Number
- NCT04830124
- Locations
- π¨π³
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
πΊπΈUT Southwestern Medical Center of Dallas, Dallas, Texas, United States
πͺπΈHospital Clinic Barcelona, Barcelona, Spain
Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: Nemvaleukin alfaBiological: Pembrolizumab
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 78
- Registration Number
- NCT04592653
- Locations
- πΊπΈ
START Mountain, West Valley City, Utah, United States
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
πΊπΈSTART Midwest, Grand Rapids, Michigan, United States
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 14
- Registration Number
- NCT04144517
- Locations
- πΊπΈ
Mural Oncology Investigational Site, Austin, Texas, United States
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
- Conditions
- Advanced Solid Tumors
- Interventions
- Biological: ALKS 4230Biological: Pembrolizumab
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 116
- Registration Number
- NCT03861793
- Locations
- π°π·
Inha University Hospital, Incheon, Korea, Republic of
π°π·Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
π°π·Seoul National University Hospital, Seoul, Korea, Republic of
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 243
- Registration Number
- NCT02799095
- Locations
- π¦πΊ
Mural Oncology Investgational Site, Albury, New South Wales, Australia
πͺπΈMural Oncology Investigational Site, Valencia, Spain
π¨π¦Alkermes Investigational Site, Toronto, Ontario, Canada